• SPX
  • $5,948.71
  • 0.53 %
  • $31.60
  • DJI
  • $43,870.35
  • 1.06 %
  • $461.88
  • N225
  • $38,283.85
  • 0.68 %
  • $257.68
  • FTSE
  • $8,199.74
  • 0.62 %
  • $50.47
  • IXIC
  • $18,972.42
  • 0.03 %
  • $6.28
Kiniksa Pharmaceuticals, Ltd. (KNSA) Stock Price, News & Analysis

Kiniksa Pharmaceuticals, Ltd. (KNSA) Stock Price, News & Analysis

Currency in USD Disclaimer

$21.11

-$0.1

(-0.47%)

Day's range
$20.71
Day's range
$21.38
50-day range
$20.26
Day's range
$28.15
  • Country: BM
  • ISIN: BMG5269C1010
52 wk range
$15.52
Day's range
$28.15


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score 7.43
  • Piotroski Score 3.00
  • Grade Overweight
  • Symbol (KNSA)
  • Company Kiniksa Pharmaceuticals, Ltd.
  • Price $21.11
  • Changes Percentage (-0.47%)
  • Change -$0.1
  • Day Low $20.71
  • Day High $21.38
  • Year High $28.15

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. Kiniksa Pharmaceuticals, Ltd. was incorporated in 2015 and is based in Hamilton, Bermuda.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) 02/26/2025
  • Fiscal Year End N/A

  • Average Stock Price Target $35.00
  • High Stock Price Target $40.00
  • Low Stock Price Target $34.00
  • Potential Upside/Downside N/A
  • Consensus Rating Sell
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) $0.13
  • Trailing P/E Ratio 146.62
  • Forward P/E Ratio 146.62
  • P/E Growth 146.62
  • Net Income $14.08 M

Income Statement

Quarterly

Annual

Latest News of KNSA

The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

Kiniksa Pharmaceuticals, Ltd. Frequently Asked Questions

  • What is the Kiniksa Pharmaceuticals, Ltd. stock price today?

    Today's price of Kiniksa Pharmaceuticals, Ltd. is $21.11 — it has decreased by -0.47% in the past 24 hours. Watch Kiniksa Pharmaceuticals, Ltd. stock price performance more closely on the chart.

  • Does Kiniksa Pharmaceuticals, Ltd. release reports?

    Yes, you can track Kiniksa Pharmaceuticals, Ltd.'s financials in yearly and quarterly reports directly on Stocks.News.

  • What is the Kiniksa Pharmaceuticals, Ltd. stock forecast?

    Watch the Kiniksa Pharmaceuticals, Ltd. chart and read a more detailed Kiniksa Pharmaceuticals, Ltd. stock forecast to see what analysts suggest you do with its shares.

  • What is Kiniksa Pharmaceuticals, Ltd. stock ticker?

    The stock ticker can vary on the respective exchange. For instance, on NASDAQ, exchange stock trades by Kiniksa Pharmaceuticals, Ltd. stock ticker.

  • How to buy Kiniksa Pharmaceuticals, Ltd. stocks?

    Like other stocks, KNSA shares are sold on stock exchanges such as NASDAQ. The best way to obtain them is through an online stock broker. Open an account, follow the broker's steps, and start trading.

  • What is Kiniksa Pharmaceuticals, Ltd.'s EBITDA?

    Kiniksa Pharmaceuticals, Ltd. measures a company's operating performance, and its growth indicates efficiency improvements. Access more stats in Kiniksa Pharmaceuticals, Ltd.’s financial statements.

  • What is the Kiniksa Pharmaceuticals, Ltd.'s net income ratio for the financial year 2023?

    The net income ratio for the financial year 2023 is 0.0521129731, which equates to approximately 5.21%. This ratio indicates the percentage of net income generated from total revenue and serves as a key measure of a company’s profitability.

  • Should I invest in Kiniksa Pharmaceuticals, Ltd. stocks?

    Investing in stocks requires thorough research. Carefully examine all available data, including Kiniksa Pharmaceuticals, Ltd.'s financials relevant news, and technical analysis. Kiniksa Pharmaceuticals, Ltd.'s technical analysis shows a “buy” rating today and a one-week “buy” rating. Since market conditions can change, it’s wise to look at longer-term trends — the one-month rating for Kiniksa Pharmaceuticals, Ltd. stock currently indicates a “sell” signal. For more insights, review Kiniksa Pharmaceuticals, Ltd.’s technical analysis.

  • A revenue figure for Kiniksa Pharmaceuticals, Ltd. for its last quarter?

    Kiniksa Pharmaceuticals, Ltd. published it's last quarterly revenues at $112.21 M.

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to Stocks.News!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.